Diagnostic value of CNV in CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, GSTP1 and GSTT1 for prediction of optimal response and failure of standard TKI therapy in CML patients (P = 6.2*10−7). The gene discussed is CYP3A5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.